Sarah Cannon Research Institute

Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024 

Retrieved on: 
Monday, April 8, 2024
Sarah Cannon Research Institute, B-cell leukemia, AML, B-ALL, Patient, Webcast, Neoplasm, Acute myeloid leukemia, Cancer, Syndrome, Spacecraft, Camptothecin, AACR, DLT, PALO, Antibody, Drug development, Safety, Infrared spectroscopy correlation table, MDS, Therapy, ADC, Drug resistance, Pharmaceutical industry

PALO ALTO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today presented positive preliminary Phase 1 data for VIP236 and updates on pipeline progress at the American Association for Cancer Research (AACR) Annual Meeting 2024.

Key Points: 
  • We are still in dose escalation and are starting to see tumor reduction after only two doses.
  • The study's main objective is to determine a safe dose and schedule for VIP236 for further clinical development.
  • As the study progresses through the dose escalation, Vincerx will present additional Phase 1 data for VIP943 on or around the 2024 European Hematology Association Annual Meeting in June 2024.
  • An archived replay of the webcast will be available on the Vincerx Investor Page website following the conclusion of the live event.

Vincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Monday, April 1, 2024
Sarah Cannon Research Institute, Webcast, Patient, Cancer, MBBS, PALO, Division, Therapy, Hematology, Pharmaceutical industry

PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, will host a virtual investor event reviewing preliminary clinical data from its Phase 1 dose-escalation study of VIP236 and provide an update on pipeline progress on Monday, April 8, 2024, at 2 PM PT.

Key Points: 
  • PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, will host a virtual investor event reviewing preliminary clinical data from its Phase 1 dose-escalation study of VIP236 and provide an update on pipeline progress on Monday, April 8, 2024, at 2 PM PT.
  • This will follow the poster presentation of the VIP236 clinical data at the AACR Annual Meeting 2024.
  • To register and view the live webcast, please visit: https://edge.media-server.com/mmc/p/xhv7kxf7/ .
  • An archived replay of the webcast will be available on the Vincerx Investor Page website following the conclusion of the live event.

SCRI Announces a Collaboration with AstraZeneca Focused on Technology Enhancements & Innovative Operational Model to Advance Cancer Research

Retrieved on: 
Wednesday, February 28, 2024
Research, Technology, Clinical Trials, Software, Biotechnology, Pharmaceutical, Health, Data Management, Science, Oncology, AstraZeneca, Electronic data capture, Physician, SCRI, Drug development, Data collection, EHR, Sarah Cannon Research Institute, Electronic health record, Patient, Clinical trial, E2E, EDC, Cancer, Pharmaceutical industry

Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, announced today a collaboration with AstraZeneca, a global, science-led biopharmaceutical company, aimed at advancing innovative technology and operational synergies to enhance the delivery of oncology clinical trials.

Key Points: 
  • Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, announced today a collaboration with AstraZeneca, a global, science-led biopharmaceutical company, aimed at advancing innovative technology and operational synergies to enhance the delivery of oncology clinical trials.
  • Working together, SCRI and AstraZeneca will implement modern solutions to accelerate clinical trial delivery timelines, reduce site burden, and enhance U.S. enrollment.
  • To date, this advancement is decreasing site-based data entry time, reducing manual labor, lowering monitoring costs, improving data quality, and accelerating clinical trial decision-making overall.
  • “Working with SCRI to enhance U.S. enrollment and streamline clinical trial data collection is a tremendous opportunity to increase the diversity of clinical trial participants in the U.S. and accelerate clinical trial delivery timelines.

Pepperdine Graziadio Business School to host 9th annual Healthcare Symposium: 'Elevating Healthcare: Exploring Solutions for the Future'

Retrieved on: 
Monday, February 12, 2024
Pepperdine University, Entrepreneurship, Health, SCRI, Future, MBA, Sarah Cannon Research Institute, Faculty, Health care, University, COVID-19, Specialization, Pepperdine Graziadio Business School, COVID, Policy, PST, Knowledge, Heart, Doorway, Student, Management

MALIBU, Calif., Feb. 12, 2024 /PRNewswire/ -- The Pepperdine Graziadio Business School will host " Elevating Healthcare: Exploring Solutions for the Future ," its 9th annual Healthcare Symposium on Thursday, Feb. 29.

Key Points: 
  • MALIBU, Calif., Feb. 12, 2024 /PRNewswire/ -- The Pepperdine Graziadio Business School will host " Elevating Healthcare: Exploring Solutions for the Future ," its 9th annual Healthcare Symposium on Thursday, Feb. 29.
  • The symposium is a marquee Graziadio event that brings industry leaders, experts and professionals together to delve into critical issues shaping the future of healthcare.
  • Pepperdine Graziadio Business School offers an array of courses tailored to meet the evolving demands of the healthcare industry.
  • The Pepperdine Graziadio Business School — for more than 50 years — has challenged individuals to think boldly and drive meaningful change within their industries and communities.

Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program

Retrieved on: 
Tuesday, December 5, 2023
CBR, Patient, Febrile neutropenia, ESR1, Breast Cancer Research, HER2, Neoplasm, Infection, Breast cancer, Fulvestrant, PFE, Colorectal cancer, Cyclin-dependent kinase 4, Chimera, Neutropenia, Melanoma, Sarah Cannon Research Institute, DNA, Incidence, Research, CDK4, ARVN, Abstract, FIH, Proteolysis, Face, Webcast, CDK, Safety, PFS, Circulating tumor DNA, Pharmaceutical industry

NEW HAVEN, Conn. and NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced clinical data for vepdegestrant (ARV-471), a novel oral PROteolysis TArgeting Chimera (PROTAC®) estrogen receptor (ER) degrader, in combination with palbociclib (IBRANCE®). Interim results from the Phase 1b combination cohort demonstrate encouraging clinical activity in heavily pre-treated patients with a median of four lines of therapy across disease settings with locally advanced or metastatic ER positive/human epidermal growth factor 2 (HER2) negative (ER+/HER2-) breast cancer. These data will be presented in a spotlight presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS).

Key Points: 
  • These data will be presented in a spotlight presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS).
  • The results from this trial evaluating vepdegestrant in combination with palbociclib help advance our goals of benefitting patients with ER+/HER2- breast cancer.
  • “Collectively, the data presented this year at SABCS for vepdegestrant, especially in combination with palbociclib, show the potential of this investigational innovative therapeutic option.
  • A conference call and webcast will be held with executives from Arvinas and Pfizer to discuss the data presented at SABCS.

The US Oncology Network Further Expands Its Nashville, Tennessee Footprint and Research Expertise with the Addition of SCRI Oncology Partners

Retrieved on: 
Tuesday, December 19, 2023
Research, Clinical Trials, Practice Management, Biotechnology, Managed Care, General Health, Health, Science, Oncology, Other Science, Network, Physician, FDA, Sarah Cannon Research Institute, Clinical trial, The Network, SCRI, Growth, MPH, Patient, Nursing

The US Oncology Network ( The Network ), the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, announced today that SCRI Oncology Partners has joined The Network.

Key Points: 
  • The US Oncology Network ( The Network ), the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, announced today that SCRI Oncology Partners has joined The Network.
  • SCRI Oncology Partners, located in Nashville, Tenn., is a dedicated cancer treatment center led by globally recognized oncologists with disease expertise in cancer care and clinical research.
  • “Increasing access to clinical trials and enhancing local cancer care are significant priorities for us,” said Jason Hammonds, president, The US Oncology Network.
  • In 2022, SCRI formed a joint venture with former US Oncology Research, the research arm of The US Oncology Network, to expand clinical trial access across the country.

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

Retrieved on: 
Monday, November 13, 2023
Doxorubicin, Squamous-cell carcinoma, Research, Netherlands Cancer Institute, City, Progression-free survival, Sarcoma, BioRxiv, Clinical trial, Patient, Northwestern, MD Anderson Cancer Center, GEIS, Monroe Dunaway Anderson, GSK, PP2A, ASTS, Sarah Cannon Research Institute, SCRI, Cancer, University, Partnership, NKI, Immunotherapy, Pharmaceutical industry

(“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy benefit, today provided an update on its progress.

Key Points: 
  • (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy benefit, today provided an update on its progress.
  • GSK will provide dostarlimab and financial support for the clinical trial.
  • In addition to MD Anderson, the trial also will be open at Northwestern University’s Robert H. Lurie Comprehensive Cancer Center.
  • This trial will enroll up to 170 patients and will begin in partnership with GEIS clinical sites.

Sarah Cannon Research Institute to Present Latest Research Insights at the 2023 ASH Annual Meeting & Exposition

Retrieved on: 
Thursday, December 7, 2023
Health, Science, Research, Clinical Trials, Oncology, HCA Healthcare, Methodist Hospital, Annual general meeting, PST, St. Elizabeth Healthcare (Kentucky), Sickle cell disease, Bone marrow, ASH, BMT, BSN, Malignancy, Exposition, Sarah Cannon Research Institute, SCRI, Abstract, Nursing care plan, Nivolumab, Society, Physician, Monomethyl auristatin E, Safety, McKesson Corporation, Pharmaceutical industry, Nursing, Vaccine, Dacarbazine, MD, Doxorubicin, Texas Oncology, Patient

Sarah Cannon Research Institute ( SCRI ) announced today that more than 80 abstracts and presentations have been selected for inclusion at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition .

Key Points: 
  • Sarah Cannon Research Institute ( SCRI ) announced today that more than 80 abstracts and presentations have been selected for inclusion at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition .
  • Hosted in San Diego and online from Dec. 9-12, the meeting is the year’s most comprehensive global hematology event.
  • At this year’s ASH Annual Meeting & Exposition, SCRI investigators, including physicians from The US Oncology Network , will discuss groundbreaking research in malignant and non-malignant blood cancer, CAR T-Cell therapy, real-world outcomes, and targeted immunotherapies.
  • Investigators highlighting research at this year’s ASH Annual Meeting & Exposition represent studies being conducted across SCRI, Sarah Cannon Transplant & Cellular Therapy Network, and partners from The US Oncology Network and Ontada.

OneOncology Appoints Ian Flinn, MD, PhD as Chief Scientific Officer

Retrieved on: 
Monday, November 20, 2023
Research, Johns Hopkins, Bone marrow, Association rule learning, Patient, St Vincent's Hospital, Sydney, Hematology, Sarah Cannon Research Institute, SCRI, Sidney Kimmel, Doctor of Philosophy, Management, Pharmaceutical industry, MD

NASHVILLE, Tenn., Nov. 20, 2023 /PRNewswire/ -- OneOncology, the fastest-growing national platform for independent oncology practices, has appointed Ian Flinn, MD, PhD, as Chief Scientific Officer.

Key Points: 
  • NASHVILLE, Tenn., Nov. 20, 2023 /PRNewswire/ -- OneOncology, the fastest-growing national platform for independent oncology practices, has appointed Ian Flinn, MD, PhD, as Chief Scientific Officer.
  • OneOncology appoints Ian Flinn, MD, PhD, as Chief Scientific Officer to oversee OneR, OneOncology's research network.
  • Dr. Flinn will also service as Chief Scientific Officer at Tennessee Oncology.
  • "Dr. Flinn will be a valuable resource for our practice partners to advance their clinical trial programs," said Davey Daniel, MD, Chief Medical Officer, OneOncology.

Tennessee Oncology Launches the Greco-Hainsworth Tennessee Oncology Centers for Research and Appoints Dr. Ian Flinn as Chief Scientific Officer

Retrieved on: 
Thursday, November 16, 2023
Johns Hopkins University, DRS, Health equity, Research, Therapy, Executive, Bone marrow, Clinical trial, Biotechnology, Patient, AROS Research Operating System, Askew, Health, Hematology, Sarah Cannon Research Institute, Oncology, SCRI, Doctor of Philosophy, Drug development, Nursing, Pharmaceutical industry, MD

Greco-Hainsworth Centers for Research brings Tennessee Oncology researchers a platform to expand world-class research.

Key Points: 
  • Greco-Hainsworth Centers for Research brings Tennessee Oncology researchers a platform to expand world-class research.
  • In parallel, Tennessee Oncology has appointed Ian Flinn, MD, PhD, as Chief Scientific Officer.
  • Heather Askew has also joined the Greco-Hainsworth Tennessee Oncology Centers for Research as the Executive Director of Research Operations.
  • "By launching the Greco-Hainsworth Tennessee Oncology Centers for Research, we're building on our core research mission to begin a new chapter of clinical trial excellence at Tennessee Oncology," said Natalie Dickson, MD, President and Chief Strategy Officer, Tennessee Oncology.